A recent Lancet article published online aims to provide internationally comparable local data on the incidence of childhood cancer to promote research of causes and implementation of childhood cancer control. Click here for the full article. ...
A New European supplier of Dinutximab Beta has been confirmed, ensuring the ongoing provision of fully-funded, standard of care immunotherapy for high-risk neuroblastoma. Click here for a full update....
New Zealand is currently investigating solutions for a shortage of dinutuximab (Unituxin, ch14.18), a FDA-approved chimeric monoclonal antibody that is used to prolong the survival of children with high-risk neuroblastoma. Click here for an update from NCCN on this shortage and steps being taken to identify...
The terms “natural”, “chemical free” and “organic” are used frequently to market personal care products. The purpose of this Research Review is to provide clarity on the meanings of these terms and the implications of their application in the marketing of personal care products. The importance of...
NCCN have just released a new guideline that provides advice on the referral of children and young people with specific cancers for genetic testing for TP53. The guideline is available on the Starship website and is indexed under TP53. Click here to access the TP53 Guideline. ...
Ministers Coleman and Joyce released the public discussion document on developing New Zealand's Health Research Strategy this Tuesday 17 May. Consultation is open until 5pm, Friday 29 July 2016. You can fill in the feedback form which is available alongside the discussion document on the Ministry...
Medical regulators and funders worldwide face seemingly impossible challenges stemming from advances in medical science, such as PMs, but limited capacity to approve and fund all such advances. It is essential that decisions regarding the regulation and funding of any new medical therapies be made...
NCCN are holding a workshop on the 3rd of May to to consider how DHBs, Ministry of Education, Schools, Health Schools, NGOs and other service providers can work with families to improve educational support and outcomes for children with cancer. We have had an overwhelming...
A recent study shows DNA sequencing brings greater precision to childhood cancer. Using genomic technology to analyze both tumor and blood samples from a large number of children who’d been newly diagnosed with cancer, an National Institutes of Health-funded research team uncovered genetic clues with...
On the 23rd of March NCCN convened a working group to consider TP53 mutation carriage and develop consistent advice on how this should be managed in the New Zealand child cancer population. Current working group members include: Kim Gamet, Genetic Health Service NZ – Northern Hub ...